arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Equillium, Inc.

EQ Health Care Biotechnology: Pharmaceutical Preparations
$2.18
▼ -1.4% Today
as of Sep 4, 16:48 ET
Last 30 days -10.16% Jul 27 → Sep 04
$1.97 $2.11 $2.25 $2.38 $2.52 Jul 27 Aug 04 Aug 12 Aug 19 Aug 27 Sep 04
Open
$2.22
High
$2.25
Low
$2.20
Volume
$225,910
Avg Vol
$670,577
Mkt Cap
$144M
P/E (TTM)
—
Beta
—
52w High
$3.54
52w Low
$0.76
Div Yield
—
Shares Out
$63M

Recent Press Releases & News last 60 days · 3 items

Sep 2 · 12:30 PR GlobeNewswire
Equillium to Participate in Upcoming Investor Conferences
Aug 13 · 20:05 PR GlobeNewswire
Equillium Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
Jul 13 · 12:14 MT Newswires
Piper Sandler Initiates Coverage on Equillium With Overweight Rating, $20 Price Target

Overview

52-week range
$0.76
$3.54
51% of range
Avg surprise (last 3)
-22.9%
Avg reaction (last 2)
-0.4%
50% positive
Latest IV / EM
250%
EM ±39.0% · $3 · Sep 18

Earnings trends

EPS — actual vs estimate Actual Estimate
$-0.24$-0.18$-0.11$-0.05$0.01 Actual $-0.11Actual $-0.10Actual $-0.11Actual $-0.08Actual $0.01Actual $-0.24Est $-0.23Actual $-0.16Est $-0.14Actual $-0.06Actual $-0.06Est $-0.04Actual $-0.04 MarJunSepMarJunSepMar/2025Jun/2025SepMar/2026Jun
Revenue vs Net Income Revenue Net income
$-9M$-3M$2M$7M$13M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Jun 30, 2026Jun 2026 $-0.04 — — — — financials
Wed May 13, 2026Mar/2026 $-0.06 $-0.04 -50.0% +75.0% +1.8% earnings
Tue Sep 30, 2025Sep 2025 $-0.06 — — — — financials
Thu Aug 14, 2025Jun/2025 $-0.16 $-0.14 -14.3% — — earnings
Wed May 14, 2025Mar/2025 $-0.24 $-0.23 -4.3% — -2.6% earnings
Mon Sep 30, 2024Sep 2024 — — — — — financials
Sun Jun 30, 2024Jun 2024 $0.01 — — — — financials
Sun Mar 31, 2024Mar 2024 $-0.08 — — — — financials
Sat Sep 30, 2023Sep 2023 $-0.11 — — — — financials
Fri Jun 30, 2023Jun 2023 $-0.10 — — — — financials
Fri Mar 31, 2023Mar 2023 $-0.11 — — — — financials

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue———————$12M
Cost of revenue————————
Gross profit————————
Operating income$-5M$-6M—$-5M$-6M$-9M—$-679,000
Net income$-5M$-5M—$-4M$-6M$-9M—$-7,000
EPS (diluted)$-0.04$-0.06—$-0.06$-0.16$-0.24——

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$57M$61M$30M$33M$11M$15M$18M$15M
Inventory————————
Total current assets$58M$62M$31M$34M$12M$16M$25M$34M
Total assets$59M$63M$32M$35M$12M$17M$26M$34M
Long-term debt————————
Total liabilities$3M$4M$3M$4M$7M$6M$7M$11M
Total equity$56M$59M$29M$31M$5M$11M$19M$23M

Implied volatility — last 90 days

51%208%366%523%680% Jun 07 — IV 233% · EM ±32.3%Jun 08 — IV 232% · EM ±30.7%Jun 09 — IV 192% · EM ±24.1%Jun 10 — IV 171% · EM ±20.2%Jun 11 — IV 237% · EM ±26.2%Jun 12 — IV 330% · EM ±33.8%Jun 15 — IV 420% · EM ±30.4%Jun 16 — IV 564% · EM ±33.3%Jun 17 — IV 681% · EM ±28.4%Jun 19 — IV 215% · EM ±47.5%Jun 22 — IV 159% · EM ±33.2%Jun 23 — IV 103% · EM ±21.1%Jun 24 — IV 162% · EM ±32.5%Jun 25 — IV 242% · EM ±47.5%Jun 26 — IV 176% · EM ±33.6%Jun 29 — IV 212% · EM ±37.5%Jun 30 — IV 168% · EM ±28.9%Jul 01 — IV 295% · EM ±49.3%Jul 02 — IV 372% · EM ±60.1%Jul 03 — IV 385% · EM ±60.1%Jul 06 — IV 222% · EM ±30.7%Jul 07 — IV 237% · EM ±31.2%Jul 08 — IV 304% · EM ±38.1%Jul 09 — IV 136% · EM ±16.0%Jul 13 — IV 478% · EM ±39.9%Jul 14 — IV 351% · EM ±25.4%Jul 15 — IV 291% · EM ±17.2%Jul 20 — IV 94% · EM ±22.3%Jul 21 — IV 82% · EM ±19.0%Jul 22 — IV 234% · EM ±53.4%Jul 23 — IV 99% · EM ±22.3%Jul 24 — IV 109% · EM ±24.1%Jul 27 — IV 117% · EM ±24.4%Jul 28 — IV 158% · EM ±32.3%Jul 29 — IV 164% · EM ±32.9%Jul 30 — IV 127% · EM ±24.8%Jul 31 — IV 59% · EM ±11.4%Aug 03 — IV 205% · EM ±36.4%Aug 04 — IV 51% · EM ±8.8%Aug 05 — IV 615% · EM ±102.7%Aug 06 — IV 635% · EM ±102.7%Aug 10 — IV 165% · EM ±22.8%Aug 12 — IV 220% · EM ±27.5%Aug 13 — IV 416% · EM ±49.1%Aug 18 — IV 235% · EM ±17.0%Aug 19 — IV 327% · EM ±19.3%Aug 20 — IV 490% · EM ±20.5%Aug 24 — IV 136% · EM ±28.4%Aug 25 — IV 106% · EM ±21.8%Aug 26 — IV 79% · EM ±15.9%Aug 27 — IV 67% · EM ±13.1%Aug 31 — IV 93% · EM ±16.5%Sep 01 — IV 105% · EM ±18.1%Sep 02 — IV 160% · EM ±26.7%Sep 03 — IV 132% · EM ±21.4%Sep 04 — IV 250% · EM ±39.0%

Sector peers

LLY
Eli Lilly and Company
$1.1T $1,148.00-0.1%
JNJ
Johnson & Johnson
$671.0B $275.71+0.2%
ABBV
AbbVie Inc.
$430.9B $256.50+0.1%
MRK
Merck & Company, Inc.
$317.1B $150.33+0.0%
PM
Philip Morris International Inc
$299.3B $182.53+0.0%
NVS
Novartis AG
$297.9B $155.11-3.0%
View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in